Pfizer's stock has struggled due to declining COVID-19 drug revenues and upcoming generic competition, keeping its price near $25.62 with a modest 6.7% dividend yield. Despite this, analysts see potential upside driven by promising new drugs in obesity, oncology, and vaccines, with a 12-month price target around $32 and a longer-term goal of $50 by 2031. Achieving $50 requires successful commercialization of new treatments like Berobenatide and sustained growth in oncology, balanced against patent risks. The stock trades at a low forward P/E of about 8x, suggesting room for multiple expansion if the pipeline delivers.
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
Roche Holding AG and Pfizer Inc. are aggressively developing new drugs targeting obesity and type 2 diabetes, aiming to capture growth in the GLP-1 market. Roche's enicepatide shows strong weight loss results in Phase 2 trials with a good safety prof...
In May, the Consumer Price Index (CPI) rose 4.2% year-over-year, matching expectations, with core CPI increasing 0.2%, slightly easing concerns about immediate Federal Reserve rate hikes. Supermicro announced plans to raise up to $7 billion through e...
